Equities

Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.20
  • Today's Change-0.02 / -0.90%
  • Shares traded778.30k
  • 1 Year change-19.12%
  • Beta1.8287
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.

  • Revenue in USD (TTM)171.36m
  • Net income in USD-64.40m
  • Incorporated2021
  • Employees377.00
  • Location
    Xeris Biopharma Holdings Inc1375 West Fulton Street, Suite 1300CHICAGO 60607United StatesUSA
  • Phone+1 (302) 658-7581
  • Fax+1 (302) 655-5049
  • Websitehttps://www.xerispharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
C4 Therapeutics Inc20.04m-126.07m301.37m145.00--1.17--15.04-2.37-2.370.36773.760.0504--2.84138,179.30-31.74-25.91-36.02-29.45-----629.24-292.35----0.00---33.251.40-3.37---8.68--
Solid Biosciences Inc0.00-90.25m303.20m88.00--1.42-----3.94-3.940.005.570.00----0.00-37.74-49.99-40.68-56.25-------2,117.05----0.0075---100.00---11.67---27.90--
Atea Pharmaceuticals Inc0.00-163.66m304.05m74.00--0.6028-----1.96-1.960.005.990.00----0.00-27.48-5.90-28.78-6.98-------38.91----0.00-------17.30------
ADC Therapeutics SA68.62m-227.23m317.42m273.00------4.63-2.77-2.770.8368-2.350.17690.26832.91251,351.60-56.99-48.41-69.99-55.6393.30---322.09-308.624.35-4.141.85---66.86127.56-52.78--5.42--
Anavex Life Sciences Corp0.00-40.59m319.10m40.00--2.34-----0.4962-0.49620.001.610.00----0.00-26.73-40.04-28.98-43.97------------0.00------0.9857------
Amarin Corporation plc (ADR)277.46m-52.61m319.70m275.00--0.5854--1.15-0.1288-0.12880.6791.330.33630.41972.231,008,927.00-6.38-4.48-8.90-6.5463.6175.70-18.96-8.591.93--0.00---16.876.0144.13--55.83--
Nautilus Biotechnology Inc0.00-67.44m320.68m163.00--1.29-----0.5402-0.54020.001.990.00----0.00-21.26---21.85--------------0.00-------9.93------
Cerus Corp191.72m-31.56m321.71m288.00--6.51--1.68-0.1742-0.17421.060.26710.96231.928.03665,680.60-15.91-25.99-24.20-40.6261.7361.90-16.53-35.811.72-2.160.6287---0.806119.6912.37--32.07--
Emergent Biosolutions Inc1.19bn-565.30m323.32m1.60k--0.487--0.2728-10.87-10.8722.8612.670.49881.996.09740,875.00-23.79-2.94-38.89-3.6641.1953.24-47.69-5.950.55380.06360.5771---6.106.05-259.40---4.29--
Alto Neuroscience Inc0.00-42.44m323.41m67.00--1.67-----1.90-1.900.007.18------0.00--------------------0.049-------31.02------
Agenus Inc161.42m-239.61m324.65m389.00------2.01-12.68-12.688.49-9.590.4823--170.54414,951.20-74.69-55.02-242.74-115.3199.43---154.88-102.92---1.25----59.4733.56-11.66--22.58--
Xeris Biopharma Holdings Inc171.36m-64.40m326.16m377.00------1.90-0.4648-0.46481.24-0.06190.52090.8385.02454,525.20-19.58-43.60-25.58-56.5782.9078.23-37.58-143.081.81-2.041.04--48.68131.5034.23--8.43--
OraSure Technologies, Inc.304.64m22.85m326.90m638.0014.540.76697.631.070.3040.3044.115.760.65732.774.31477,493.704.930.72385.420.821245.2646.947.501.1310.49--0.00170.004.6417.41413.1782.2010.18--
Organogenesis Holdings Inc435.47m5.82m330.77m862.0057.381.1815.580.75960.04350.04353.282.110.96284.084.63505,190.301.295.461.566.9075.0774.941.344.812.418.780.19550.00-3.9417.49-68.16--67.34--
Black Diamond Therapeutics Inc0.00-79.79m335.83m54.00--3.01-----1.70-1.700.001.990.00----0.00-57.38-40.29-64.24-43.29------------0.00------9.57---15.37--
Verrica Pharmaceuticals Inc8.91m-80.74m344.45m100.00--228.42--38.65-1.75-1.750.19290.03560.1321--2.3389,130.00-119.66-55.75-142.98-78.3379.63---905.83-754.943.04-21.710.9678---43.27---173.59--5.65--
Data as of Jun 14 2024. Currency figures normalised to Xeris Biopharma Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

24.29%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Mar 20248.85m5.97%
The Vanguard Group, Inc.as of 31 Mar 20247.33m4.95%
Caxton Corp.as of 31 Mar 20245.11m3.45%
SSgA Funds Management, Inc.as of 31 Mar 20243.22m2.17%
Geode Capital Management LLCas of 31 Mar 20243.05m2.05%
Rosalind Advisors, Inc.as of 31 Mar 20242.82m1.90%
Millennium Management LLCas of 31 Mar 20241.70m1.14%
CenterBook Partners LPas of 31 Mar 20241.54m1.04%
TIAA-CREF Investment Management LLCas of 31 Mar 20241.23m0.83%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 20241.16m0.78%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.